Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website

SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education (ACE) to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, is now available on the website for the December 2023 San Antonio Breast Cancer Symposium (SABCS). The complete set of abstracts submitted to SABCS 2023 can be viewed by clicking here.

"While cancer treatments have advanced considerably since the advent and availability of targeted therapies, significant short- and long-term treatment side effects can be challenging or even devastating to an individual's quality of life (QoL)," said Advocates for Collaborative Education founder Stacey Tinianov, MPH, a member of the Jaguar/Napo Scientific Advisory Board. "Management of treatment side effects is integral to supportive care. The collaboration with patients and survivors in developing this survey represents a pivotal step in determining areas that demand attention for improving QoL and offers valuable insights aimed at enhancing the well-being of individuals affected by cancer and additional research will pursue collaborative solutions. I look forward to the poster presentation of the breast cancer-related results of the survey on December 7^th at SABCS."

Across a wide range of demographic subsets, including age, race, stage of cancer, and treatment modalities, 334 survey respondents with a history of breast cancer reported a decline in QoL scores precancer versus post-cancer. Physical and emotional well-being emerged as top priorities for most respondents, 47.9% and 27.5% respectively. Of 17 listed side effects, respondents cited fatigue (49%), muscle/joint pain (36%), and emotional distress (35%) as primary concerns, with sexual dysfunction and cognitive impairment ranking prominently. Forty-six percent reported severe to very severe emotional distress, but only 55% of those felt informed or well informed about the possibility of emotional distress. Among respondents, only 41% received a plan to address emotional distress.